Clinical trial NCT01477853: A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Official title: A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Type 2 Diabetes Mellitus
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2011-11-23
Enrollment: 166
Sex: ALL
Minimum age (years): 18
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This two-phase study was to examine if 16 weeks of treatment with sitagliptin in combination with atorvastatin reduces hemoglobin A1C (A1C) and low density lipoprotein cholesterol (LDL-C) from baseline more than atorvastatin alone and sitagliptin alone, respectively. Following a single-blind placebo run-in period, participants were to be randomized to one of three treatment arms (sitagliptin monotherapy, atorvastatin monotherapy, or sitagliptin plus atorvastatin) for 16 weeks (Phase A). During Phase B of the study (Weeks 16 through 54), participants were to receive either sitagliptin plus atorvastatin or glimepiride plus atorvastatin. The primary hypotheses were that after 16 weeks of treatment, sitagliptin in combination with atorvastatin reduces A1C from baseline more than atorvastatin alone, and that atorvastatin in combination with sitagliptin lowers LDL-C from baseline more than sitagliptin alone.


Eligibility criteria: Inclusion Criteria:

* has type 2 diabetes mellitus
* is a male, or a female who is highly unlikely to conceive
* is currently on monotherapy with metformin (at least 1500 mg/day) for at least 8 weeks
* is not on statin therapy or other lipid-lowering agents for at least 6 weeks

Exclusion Criteria:

* has a history of type 1 diabetes mellitus, ketoacidosis or possibly has type 1 diabetes
* has ever taken a dipeptidyl peptidase IV inhibitor (such as sitagliptin, vildagliptin, alogliptin, or saxagliptin) or a glucagon-like peptide-1 mimetic (such as exenatide or liraglutide), or has required insulin therapy within 12 weeks prior to signing informed consent
* has been on a peroxisome proliferator-activated receptor gamma agonist within the prior 12 weeks
* has been treated with a statin or other lipid-lowering agents, including over the counter supplements of fish oils within 6 weeks
* intends to consume at least 1.2 liters of grapefruit juice per day during the course of the study
* is on or is likely to require treatment with 14 consecutive days or more, or repeated courses of corticosteroids
* is on a weight loss program and not in the maintenance phase or has started a weight loss medication (such as orlistat or sibutramine) within the prior 8 weeks
* has undergone a surgical procedure within the prior 4 weeks
* has a history of myopathy or rhabdomyolysis with any statin.
* has cardiovascular disease
* has New York Heart Association (NYHA) Class III or IV congestive heart failure, inadequately controlled hypertension, a medical history of active liver disease, chronic progressive neuromuscular disorder, is human immunodeficiency virus (HIV) positive, has a clinically significant hematological disorder, uncontrolled endocrine or metabolic disease known to influence glycemic control or serum lipids/lipoproteins, untreated hyperthyroidism or is currently under treatment for hyperthyroidism
* has a history of malignancy within 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
* is pregnant or breastfeeding, or is intending to become pregnant or donate eggs within the projected duration of the study and post-study follow-up period
* uses recreational or illicit drugs or has had a recent history (within the last year) of drug abuse or increased alcohol consumption

Primary outcomes:
measure: Change From Baseline in Hemoglobin A1C (A1C) at Week 16
timeFrame: Baseline and Week 16
measure: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 16
timeFrame: Baseline and Week 16
measure: Number of Participants Who Experienced at Least One Adverse Event
timeFrame: Up to 56 weeks (including 2-week follow-up)
measure: Number of Participants Who Discontinued Study Drug Due to an Adverse Event
timeFrame: Up to 54 weeks
Secondary outcomes:
measure: Change From Baseline in Fasting Plasma Glucose (FPG) at Week 16
timeFrame: Baseline and Week 16
measure: Percent Change From Baseline in Total Cholesterol at Week 16
timeFrame: Baseline and Week 16
measure: Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 16
timeFrame: Baseline and Week 16
measure: Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C) at Week 16
timeFrame: Baseline and Week 16
measure: Percent Change From Baseline in Triglycerides at Week 16
timeFrame: Baseline and Week 16
measure: Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 16
timeFrame: Baseline and Week 16
measure: Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 16
timeFrame: Baseline and Week 16
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Director
role: STUDY_DIRECTOR
References: